Are You Age 50 or Older and HAD A PNEUMOCOCCAL VACCINE A YEAR OR MORE AGO?
Consider The STRIDE-6 Clinical Research Study.
Pneumococcal disease is an illness caused by certain germs (bacteria), called Streptococcus pneumoniae. These germs can cause serious infections in the ears, nose, lungs, blood, or brain.
Vaccines help the body fight infections due to diseases like pneumococcal disease, and may help prevent serious illness. New vaccines must be tested to show that they work.
The STRIDE-6 study is testing an investigational study vaccine (V116) to see if it can help protect against pneumococcal disease. This trial will compare V116 to VaxneuvanceTM (pneumococcal 15-valent conjugate vaccine) and Pneumovax23® (pneumococcal 23-valent conjugate vaccine). Both VaxneuvanceTM and Pneumovax23® are approved for preventing pneumococcal disease in some countries but may not be approved in your country. This study will evaluate the safety of V116 and see how well the vaccine works and how your body responds to the vaccine compared to VaxneuvanceTM and Pneumovax23®.
The study will also evaluate how the body handles the investigational study vaccine and how it protects adults who were previously vaccinated with 1 or more pneumococcal vaccines.
You may qualify for this study if you are 50 years of age or older and:
• Have previously received 1 or more pneumococcal vaccines at least 1 year ago
• Have not had a positive test (culture) for pneumococcal disease within the last 3 years
Additional requirements apply.
If you qualify and agree to take part, you will get a dose of the investigational study vaccine or VaxneuvanceTM and Pneumovax23®.
The study vaccines and study-related tests will be provided at no cost. You may also be reimbursed for study travel and related expenses.
For more information, including the possible
risks and benefits of participation, please contact: 786-772-0510